TABLE 1.
Baseline characteristics
| Variables | Overall (n = 971) | Men (n = 369) | Women (n = 602) | p‐Value |
|---|---|---|---|---|
| Age (years) | 66.5 ± 11.4 | 64.2 ± 12.3 | 67.8 ± 10.7 | <.001 |
| SBP (mm Hg) | 137.0 ± 16.7 | 136.9 ± 15.8 | 137.1 ± 17.2 | .893 |
| DBP (mm Hg) | 81.9 ± 10.5 | 83.8 ± 10.7 | 80.8 ± 10.2 | <.001 |
| Heart rate (beat per minute) | 71.7 ± 12.0 | 72.0 ± 12.3 | 71.5 ± 11.8 | .572 |
| Smoking, n (%) | 208 (21.4) | 203 (55.0) | 5 (0.8) | <.001 |
| Physical inactivity, n (%) | 408 (42.0) | 148 (40.1) | 260 (43.2) | .38 |
| Body surface area (m2) | 1.62 ± 0.18 | 1.73 ± 0.15 | 1.55 ± 0.15 | <.001 |
| Body mass index (kg/m2) | 25.3 ± 3.8 | 24.9 ± 3.5 | 25.5 ± 3.9 | .024 |
| Obesity, n (%) | 205 (21.1) | 61 (16.5) | 144 (23.9) | .008 |
| Waist/hip ratio | 0.93 ± 0.06 | 0.94 ± 0.05 | 0.92 ± 0.06 | <.001 |
| Dyslipidemia, n (%) | 597 (75.6) | 209 (71.1) | 388 (78.2) | .03 |
| Diabetes mellitus, n (%) | 216 (22.3) | 75 (20.3) | 141 (23.5) | .283 |
| Hyperuricemia, n (%) | 614 (64.7) | 244 (67.4) | 370 (63.0) | .194 |
| CKD, n (%) | 124 (13.3) | 50 (14.0) | 74 (12.8) | .684 |
| FPG (mmol/L) | 5.4 ± 1.5 | 5.3 ± 1.6 | 5.4 ± 1.5 | .379 |
| Total cholesterol (mg/dl) | 211.1 ± 53.5 | 200.1 ± 49.6 | 217.9 ± 54.7 | <.001 |
| LDL cholesterol (mg/dl) | 129.1 ± 38.4 | 125.3 ± 37.2 | 131.6 ± 39.0 | .072 |
| HDL cholesterol (mg/dl) | 53.5 ± 14.4 | 50.2 ± 16.1 | 55.7 ± 12.7 | <.001 |
| Triglyceride (mg/dl) a | 132.6 [96.2, 190.7] | 128.5 [93.6, 190.1] | 135.0 [97.5, 193.2] | .994 |
| Creatinine (µmol/L) | 79.3 ± 35.1 | 94.7 ± 46.0 | 69.7 ± 21.2 | <.001 |
| eGFR (ml/min/1.73 m2) | 83.5 ± 24.0 | 82.4 ± 23.8 | 84.2 ± 24.1 | .27 |
| Uric acid (µmol/L) | 429.2 ± 124.2 | 471.4 ± 121.9 | 403.2 ± 118.3 | <.001 |
| Aspirin, n (%) | 167 (17.2) | 73 (19.8) | 94 (15.6) | .113 |
| Statins, n (%) | 272 (28.0) | 112 (30.4) | 160 (26.6) | .231 |
| Oral antidiabetics, n (%) | 175 (18.0) | 64 (17.3) | 111 (18.4) | .73 |
| Insulin, n (%) | 4 (0.4) | 3 (0.8) | 1 (0.2) | .312 |
| Allopurinol, n (%) | 22 (2.3) | 12 (3.3) | 10 (1.7) | .163 |
| ACEI, n (%) | 144 (14.8) | 62 (16.8) | 82 (13.6) | .207 |
| ARB, n (%) | 489 (50.4) | 187 (50.7) | 302 (50.2) | .929 |
| CCB, n (%) | 454 (46.8) | 166 (45.0) | 288 (47.8) | .424 |
| Diuretic, n (%) | 137 (14.1) | 63 (17.1) | 74 (12.3) | .047 |
| Betablocker, n (%) | 127 (13.1) | 48 (13.0) | 79 (13.1) | 1 |
| No. antihypertensive drugs a | 1.00 [1.00, 2.00] | 1.00 [1.00, 2.00] | 1.00 [1.00, 2.00] | .302 |
Abbreviations: ACEI, angiotensin‐converting enzyme inhibitor; ARB, angiotensin receptor blocker; CCB, calcium channel blocker; CKD, chronic kidney disease; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; FPG, fasting plasma glucose; HDL, high‐density lipoprotein; LDL, low‐density lipoprotein; SBP, systolic blood pressure.
a
Presented as median [Q1, Q3].